Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination

Background. The most common cause of noncurative resection and recurrence in gastric cancer is peritoneal seeding. However, the results of treatment of peritoneal dissemination with chemotherapy have been. poor with 5-year survival rates of 0%. Methods. A new in vitro thermochemosensitivity test was performed on gastric cancer cells obtained from 19 surgically resected specimens by using tetrazolium-based colorimetric assay (MTT assay). A novel treatment of the intraoperative chemohyperthermia was undertaken in. 83 patients with gastric cancer with peritoneal dissemination. After aggressive resection of primary tumor, lymph nodes, and peritoneal metastases, warned saline solution containing mitomycin. C 30 mg, etoposide 150 mg, and cisplatin 300 mg was introduced into the peritoneal cavity via a closed circuit continuous hyperthermic peritoneal perfusion (CHPP) for 60 minutes to keep the abdominal temperature at 42 degrees to 43 degrees C by means of a heat exchange mechanism. Results. The in vitro thermochemosensitivity test showed that 43 degrees C enhanced the cytotoxic effects on. gastric cancer cells under clinically achievable drug concentrations. During CHPP, drug concentrations of cisplatin, mitomycin C, and etoposide in the perfusate remained statistically higher than in the peripheral venous circulation. Among 43 evaluable patients with residual peritoneal seeding, eight (19%) and nine (21%) exhibited complete response and partial response, respectively. The overall 1-and 5-year survival rates were 43% and 11%, respectively. Patients who underwent complete resection survived significantly longer than those with residual disease, and those with complete response had a significantly better prognosis than did those with partial response or nonresponders. One-year survival rates of patients with complete response, partial response, and nonresponders were 88%, 27%, and 22%, respectively. Five patients survived longer than 5 years. Conclusions. Our triple treatment combining surgery and CHPP is an effective therapy for selected patients with gastric cancer with peritoneal dissemination.